



euroPLX

Business Developer

Vol. 14 # 11 | November | 2018

Brexit Offers Opportunities, Too. At euroPLX 69 London - Secure Your Place Now!

* Acquisition: **Alexion Pharmaceuticals, Inc.** completed the previously announced acquisition of **Syntimmune**. The acquisition adds to the company's growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with Immunoglobulin G (IgG) and IgG immune complexes with the potential to treat a number of rare IgG-mediated diseases. 2 Nov 2018 (www.alxn.com)

* Licensing: **Amyris, Inc.**, has already expanded its original collaboration with **Yifan Pharmaceutical Co., Ltd.** from its September 2018 agreement. Yifan will add a second molecule from Amyris to its vitamin portfolio. One of the leading Chinese pharmaceutical companies, Yifan focuses on innovation, R&D, manufacturing and sales of active pharmaceutical ingredients including nutritional products, and traditional Chinese medicines. 8 Nov 2018 (www.amyris.com)

* Divestiture: **Cipla Ltd.**'s subsidiary **InvaGen Pharmaceuticals Inc.** has entered into definitive agreements with two closing stages for a proposed acquisition of **Avenue Therapeutics, Inc.**, a company focused on the development and commercialisation of intra-

venous (IV) Tramadol. 13 Nov 2018 (www.cipla.com)

* Acquisition: **CytoDyn Inc.**, a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that on Friday November 16, 2018 it completed the previously announced acquisition of privately held **ProstaGene, LLC**. The total transaction value was approximately \$15.4 million. 19 Nov 2018 (www.cytodyn.com)

* Acquisition: The **Grünenthal Group** has agreed to acquire **AstraZeneca's** European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US\$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium. It is indi-

cated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric and/or duodenal ulcers. 30 Oct 2018 (www.grunenthal.com)

* Acquisition: The **Grünenthal Group** has acquired the US-based pharmaceutical company **Averitas Pharma**, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics. 14 Nov 2018 (www.grunenthal.com)

* Distribution: **Lannett Company, Inc.** has entered into an agreement with **Amneal Pharmaceuticals, Inc.** with regard to Levothyroxine Sodium Tablets USP. Under the agreement, Amneal will be Lannett's sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers. Lannett will receive an upfront payment of \$50 million, other terms of the transaction were not disclosed. 12 Nov 2018 (www.lannett.com)

* Commercialisation: **Moberg Pharma** signed an exclusive agreement with **Mundipharma** to commercialise Emtrix®, Moberg's lead fungal nail product. Moberg Pharma will exclusively supply the product, and Mundipharma will be responsible for local registration and commercialisation in the Middle East and Africa, focusing initially on three markets in the region. 5 Nov 2018 (www.moberg-derma.se)

BD People on the Move

* Antibe Therapeutics Inc: **Angus Russell, Dominique Monnet, Andrew Powell** and **Rami Batal** have been appointed to the company's Business Development Advisory Board. (Press Release 22 Oct 2018)

* Dr. Reddy's Laboratories Ltd.: **Nicole Rengstorf**, who has been Associate Director Out-Licensing, has left the company. (Pers Comm 29 Oct 2018)

* Grupo Menarini: **Daniel Inarejos**, until recently Business Development Manager at Hetero Europe S.L., has been appointed as Business Development & Licensing Manager responsible for LATAM. (Pers Comm 15 Nov 2018)

* Kamada Ltd.: **Eitan Kyiet**, who served as Chief Operating

Officer of PolyPid, a clinical-stage emerging biopharmaceutical company, has been appointed as Vice President of Business Development. (Press Release 24 Oct 2018)

* **Pharmaceutics International**, Inc.: **Hank Nowak**, who most recently served as the Head of Global Business Development at Metabolon, Inc., has been appointed as Vice President of Business Development (Press Release 13 Nov 2018)

Newcomers to euroPLX 68 Athens (part 2)

Since the first euroPLX Conference in 1995 more than 1,700 pharmaceutical and biotechnology companies have attended this partnering conference. Although many of them keep returning, euroPLX has managed to attract 10 to 20% newcomers to each of the past 67 conferences. Here are some first-time attendees that have registered for euroPLX 68 Athens:

Acidima BioCenter (www.acidima.com) is based in Amman, Jordan. As a Contract Research Organization Acidima focuses on bioequivalence and pharmaceutical studies.

AFCO SA is a Greek privately owned company. In the pharmaceutical sector AFCO represents companies and offers service to pharmaceutical developers for licensing generic pharmaceutical products in the Balkan area.

Alrazi Pharma Industries Ltd (www.alrazi-pharma.com) is based in Dammam, Saudi Arabia, producing and delivering quality products across Saudi Arabia and Arabian Gulf region in compliance with the highest international standard.

Based in Hanoi, Vietnam, **Anminh Pharma Company** (www.anminhpharma.com.vn) imports and distributes a wide range of quality, affordable generic medicines, food supplements and medical devices, trusted by healthcare professionals and patients in Vietnam.

Germany-based **Artesan Pharma GmbH** is part of the Klosterfrau Group. As a mid-sized German CDMO with more than 50 years experience in the development and manufacturing of RX, OTC, Medical and Phyto products the company has five GMP approved plants in Germany for the manufacture of solids, lozenges, liquids

and gel syringes and deliver high quality and cost-effective solutions to our customers.

Headquartered in Buenos Aires and with offices in Uruguay and Mexico, as well as representations in other South American countries, **Conderco** (www.conderco.net) represents manufacturing companies for both, API & FDF through LATAM region.

As one of the most prominent companies in Israel engaged in the healthcare, the **CTS Group** (www.cts.co.il) imports, exports, develops, manufactures and market prescription drugs, OTC medications and medical devices - diagnostics and genetics. The company's Healthcare Division manufactures and exports pharmaceutical products, dermo-cosmetics and toiletries to Australia, Hong Kong, UK, South Africa, Turkey, Central and Eastern European countries, USA and Russia.

Based in Brescia, Italy, **Gruppo Farmaimpresa Srl** (www.farmaimpresa.com) focuses on design, development, patent and manufacture of innovative medical devices (class I, II, III), food supplements and dermo cosmetics. The company's products are sold in

more than 30 countries and our portfolio is composed of more than 150 products.

Medreich (www.medreich.co.uk) is based in London and specialises in generic pharmaceuticals, with an established presence across the globe and active in the United Kingdom with its own label. Since 2015 the company is part of the Japanese Meiji Group.

OAHealth is a rapidly expanding independent Dutch medical service company active in medical healthcare and the pharmaceutical industry. OAHealth is actively engaged in licensing, partnering, developing and marketing late-stage specialty medicines as well as medical devices and consumer brands.

India-based **RA Chem Pharma** (www.rachempharma.com), is a vertically integrated generic pharmaceutical company offering API, formulations and clinical research. All the sites of RA Chem Pharma, a API manufacturing facility, a solid dosage formulation manufacturing facility, and a Clinical Research & Biosciences division are approved by US FDA, EDQM/ EU GMP, TGA Australia, Health Canada etc.

Insanely Effective Pharma Partnering

euroPLX is the world's most often held partnering conference for the pharma and biopharma industries. Because of results delivered. Year-round.

Join the 69th International Partnering Conference for Pharma Business Development*

*euroPLX 69 London (UK)

February 25 + 26, 2019, Sofitel London Heathrow

Seeking and offering business opportunities in patented and generic (incl. biosimilars), prescription and OTC drugs, medical devices, and nutraceuticals - development, licensing, marketing, promotion, and distribution...

Each euroPLX Conference's actual collaboration interests are summarised and displayed on www.europlx.com as an hourly updated **Dynamic Partnering Focus**, as soon as sufficient data are submitted by registrants.

 **euroPLX**
by RauCon

www.europlx.com
meetyou@europlx.com
ph. ++49 (6221) 426296-0

The Original since 1995.
Often copied. Never equaled.

